The liquidity contract signed on September 14, 2009 has been terminated by INNATE PHARMA and NATIXIS. The termination is effective from August 31, 2012 after market.
As at August 31, 2012, the following assets appeared on the liquidity account:
- 51,099 shares of Innate Pharma, and
- 219,813.87 euros in cash.
INNATE PHARMA and GILBERT DUPONT signed on August 24, 2012 a new liquidity contract in compliance with the AMAFI charter which will be effective on September 4, 2012 before market.
For the implementation of this new liquidity contract, the following assets appear on the liquidity account:
- 51,099 shares of Innate Pharma, transferred from the previous liquidity contract, and
- 219,813.87 euros in cash from the previous liquidity contract.
| PR in English | 37.44 KB |
| CP en français | 33.61 KB |